A Fiocruz tem produzido uma série de materiais informativos sobre a pandemia da doença pelo SARS-CoV-2 (Covid-19). A reprodução do material é livre e gratuita. Baixe e compartilhe informação correta e de qualidade.
Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk of severe COVID-19, NPI are the most effective public health interventions against... COVID-19. These ECDC guidelines detail available options for NPI in various epidemiologic scenarios, assess the evidence for their effectiveness and address implementation issues, including potential barriers and facilitators.
more
In the light of the transmissibility of coronaviruses, and the global experience with MERS-CoV (ongoing) and SARS in 2003 which were also caused by coronaviruses, South African authorities have compiled this guideline document to support surveillance, case finding, diagnosis, management and public h...ealth responses to cases under investigation.
*Please note*
The interim guidelines are based on what is currently known about the Coronavirus Disease 2019 (COVID-19). The National Department of Health (NDOH) and National Institute for Communicable Diseases will update these interim guidelines as needed and as additional information becomes available.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
COVID-19: occupational health and safety for health workers: interim guidance, Interim guidance 2 February 2021
Health workers are at the front line of the COVID-19 outbreak response and as such are exposed to different hazards that put them at risk. Occupational hazards include exposure to SARS-C...oV-2 and other pathogens, violence, harassment, stigma, discrimination, heavy workload and prolonged use of personal protective equipment (PPE). This document provides specific measures to protect occupational health and safety of health workers and highlights the duties, rights and responsibilities for health and safety at work in the context of COVID-19.
more
Issue Brief no.8. January 18,2021
Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies,... implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages.
more
A COVID-19 virus mutation tracker system (CovMT; appendix) based on SARS-CoV-2 isolate genomes deposited to GISAID to track the worldwide sequencing efforts and the evolution of the mutational landscape of this virus. CovMT, which is updated daily, summarises mutations from more than 450 000 isola...tes into groups of generic virus clades, lineages, and more specific mutation sets we call mutation fingerprints.
more
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
Ausführliche Informationen zu klinischen Prüfungen und Risiken für bestimmte Gruppen sowie zu Wechselwirkungen und Nebenwirkungen von Impfstoffen und Arzneimitteln zu COVID-19 und SARS-CoV-2
El presente material es un aporte NO OFICIAL y volutario realizado a partir de la reunión clínica del equipo de Infectología Pediátrica PUC. Su objetivo
de aportar con un recurso educativo que contribuya a la actualización de los profesionales y estudiantes de la salud respecto a este problem...a de salud global.
La pandemia por SARS-CoV2 es una amenaza respecto a la cual existe un flujo de información en permanente y rápido cambio. Complemente siempre su lecturas con fuentes actualizadas.
more
Острая респираторная вирусная инфекция (ОРВИ) – острое
инфекционное заболевание респираторного тракта, проявляющееся
воспалением верхних дыхательных путей, в б...ольшинстве случаев
завершающееся спонтанным выздоровлением. ОРВИ, как правило, протекает с
катаральными симптомами (насморком, кашлем, болью в горле и др.),
признаками общей интоксикации, субфибрильной, реже фибрильной,
лихорадкой.
Основными возбудителями ОРВИ являются вирусы гриппа типа А и В,
респираторно-синцитиальный вирус (РСВ), вирусы парагриппа, риновирусы,
аденовирусы, человеческие метапневмовирусы, бокавирусы, сезонные
коронавирусы. Вирусы, способные вызывать тяжелые пневмонии, такие как
MERS-CoV и SARS-CoV-2 (возбудитель новой коронавирусной инфекции
COVID-19), могут клинически протекать как сезонные ОРВИ. Также
необходимо помнить, что ОРВИ могут иметь сочетанную этиологию, когда в
развитии инфекционного процесса участвует несколько возбудителей. (версия 2 16.04.2020)
medical treatment for acute respiratory viral infections in outpatient practice during the COVID-19 epidemic
more
Esta é a primeira edição de orientações sobre estratégias de prevenção e controle de infecção (PCI) para utilizar quando houver suspeita de infecção por um novo coronavírus (2019-nCoV). Foi adaptado do guia da OMS de Prevenção e controle de infecções durante os cuidados de saúde pa...ra casos prováveis ou confirmados da infecção pelo coronavírus que causa a síndrome respiratória do Oriente Médio (MERS--CoV)1, com base no conhecimento atual da situação na China e em outros países onde foram identificados casos e experiências com a síndrome respiratória aguda grave (SARS)-CoV e MERS-CoV. A OMS atualizará essas recomendações assim que novas informações estiverem disponíveis. Esta orientação destina-se a profissionais de saúde, gerentes de saúde e equipes de PCI na atenção básica em saúde, mas também é relevante para os níveis nacional e subnacional. Diretrizes completas estão disponíveis na OMS.
more
Das Tragen von Mund-Nasen-Bedeckungen kann neben anderen Maßnahmen nach aktuellem Wissensstand helfen, die Verbreitung des Coronavirus SARS-CoV-2 weiter einzudämmen – auch wenn keine Krankheitszeichen vorliegen. Dieses Merkblatt informiert über verschiedene Arten von Mund-Nasen-Bedeckungen, der...en jeweilige Schutzfunktion, welche wann empfohlen wird und was beim Tragen zu beachten ist.
more
23 Dec 2020. The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmissio...n to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020
more
Evidencias COVID-19 es un recurso que ofrece información relevante relacionada con la pandemia del coronavirus SARS-CoV-2 y la COVID-19.
Este recurso recoge una serie de documentos que sintetizan la información más relevante para dar respuesta a preguntas clínicas y temas prioritarios sobre l...a pandemia, en forma de revisiones de la literatura y evaluaciones críticas de estudios. Los documentos han sido elaborados por integrantes de la Red Cochrane Iberoamericana con la intención de sintetizar y actualizar el conocimiento disponible en relación con la COVID-19 y son compartidos con la intención de dar una respuesta colaborativa a la situación actual.
more
Dieser Leitfaden zum Management von COVID-19 Ausbruechen richtet sich in erster Linie an die Fachöffentlichkeit im Gesundheitswesen, insbesondere den ÖGD auf allen Ebenen. Er verweist auf viele bereits existierende generische sowie für COVID-19 entwickelten Dokumente. Diese Empfehlungen sind alle... unter www.rki.de/covid-19 zu finden, darunter Empfehlungen für das Kontaktpersonenmanagement, Optionen für die Kontaktreduzierung, Kriterien für die Risiköinschätzung von Grossveranstaltungen und Hilfestellung zum Schutz besonders gefährdeter Gruppen. Informationen für Reisende sind beim Auswärtigen Amt zu finden. Informationen zur regionalen oder lokalen Ebene geben die Landes- und kommunalen Gesundheitsbehörden.
Die Inhalte basieren auf den Erkenntnissen zu Erkrankungen (COVID-19) mit Infektionen durch das neuartige Coronavirus (SARS-CoV-2) zum jeweils angegebenen Datenstand. Das Dokument wird aktualisiert und ergänzt, sobald neue Erkenntnisse eine Aktualisierung/Änderung der Empfehlungen notwendig machen.
more
Letzte Aktualisierung: 19.06.2020
Krebspatientinnen und Krebspatienten sind nach Aussage der Experten durch das neuartige Coronavirus (SARS-CoV-2) besonders gefährdet.
Viele Betroffene sind nun sehr verunsichert: Wie wirkt sich das Virus auf die Krebstherapie aus? Gehöre ich überhaupt z...ur Risikogruppe? Und was muss ich jetzt mit oder nach meiner Krebserkrankung im Alltag beachten?
Der Krebsinformationsdienst des Deutschen Krebsforschungszentrums beantwortet in diesem Beitrag häufige Fragen zum Thema "Corona und Krebs"
more
J Bras Pneumol. 2022;48(2):e20220082
The spread of Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) continues to progress, causing damage in several countries of the world due to its rapid transmissibility and significant mortality rates, despite government measures to contain its tra...nsmission, such as movement control, the closing of schools, bans on travel and public gatherings, the mandatory use
of masks, and hand hygiene. The coronavirus disease (COVID-19) has clinical manifestations that are similar to those found in other infections also transmitted through the airways, such as pulmonary tuberculosis (TB) Although TB is a global health problem, it is a curable disease, with affordable treatment and prevention. Nonetheless, it remains one of the leading
causes of death from a single infectious agent worldwide, a situation threatened by COVID-19.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Update 1 October 2020.
This document provides guidance to Member States on the effective use of face masks/coverings in the community by individuals without COVID-19 symptoms in order to reduce potential transmission of SARS-CoV-2.a It also provides advice on the use of masks during home care for ...patients with COVID-19.
more